Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

<h4>Background</h4> Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daphne M. V. de Vries–Huizing, Michelle W. J. Versleijen, Michiel Sinaasappel, Iris Walraven, Martine M. Geluk–Jonker, Margot E. T. Tesselaar, Jeroen J. M. A. Hendrikx, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/10f604e4a7ac41138d1d16ddeede3576
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10f604e4a7ac41138d1d16ddeede3576
record_format	dspace
spelling	oai:doaj.org-article:10f604e4a7ac41138d1d16ddeede35762021-11-25T06:19:38ZHaematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course1932-6203https://doaj.org/article/10f604e4a7ac41138d1d16ddeede35762021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601524/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this study was to evaluate the haematotoxicity course during PRRT and to compare baseline parameters between haematotoxicity grades. <h4>Methods</h4> In this retrospective study, 100 patients with a neuroendocrine tumour treated with PRRT were included. Patients were treated with an aimed number of four cycles with 7.4 GBq [177Lu]Lu-DOTA-TATE administered every 10 weeks. Haematological assessment was performed at baseline and frequently up to 10 weeks after the fourth cycle. The lowest haematological value was graded according to CTCAE v5.0, and patients were classified using the highest observed grade. Differences in baseline parameters, including [68Ga]Ga-DOTA-TATE positive tumour volume, were evaluated between CTCAE grades. <h4>Results</h4> Four cycles were completed by 86/100 of patients, 4/100 patients discontinued due to haematotoxicity, and 10/100 patients due to progressive disease. The treatment course was adjusted due to haematotoxicity in 24/100 patients, including postponed next cycle (n = 17), reduced administered activity (n = 13), and both adjustments (n = 10). The most observed haematotoxicity grade was grade 0–1 in 54/100 patients, grade 2 in 38/100 and grade 3–4 in 8/100. Significant differences in baseline leucocyte, neutrophil and platelet counts were observed between grade 0–1 and grade 2. However, the correlation between baseline and lowest observed values was poor to moderate. No differences between haematotoxicity grades and baseline parameters or somatostatin receptor positive tumour volume was observed. <h4>Conclusions</h4> The incidence of severe haematotoxicity was low with extensive screening and monitoring. The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment. Baseline parameters showed limited correlation with the degree of decline in haematological values.Daphne M. V. de Vries–HuizingMichelle W. J. VersleijenMichiel SinaasappelIris WalravenMartine M. Geluk–JonkerMargot E. T. TesselaarJeroen J. M. A. HendrikxBerlinda J. de Wit–van der VeenMarcel P. M. StokkelPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Daphne M. V. de Vries–Huizing Michelle W. J. Versleijen Michiel Sinaasappel Iris Walraven Martine M. Geluk–Jonker Margot E. T. Tesselaar Jeroen J. M. A. Hendrikx Berlinda J. de Wit–van der Veen Marcel P. M. Stokkel Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
description	<h4>Background</h4> Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy management. The aim of this study was to evaluate the haematotoxicity course during PRRT and to compare baseline parameters between haematotoxicity grades. <h4>Methods</h4> In this retrospective study, 100 patients with a neuroendocrine tumour treated with PRRT were included. Patients were treated with an aimed number of four cycles with 7.4 GBq [177Lu]Lu-DOTA-TATE administered every 10 weeks. Haematological assessment was performed at baseline and frequently up to 10 weeks after the fourth cycle. The lowest haematological value was graded according to CTCAE v5.0, and patients were classified using the highest observed grade. Differences in baseline parameters, including [68Ga]Ga-DOTA-TATE positive tumour volume, were evaluated between CTCAE grades. <h4>Results</h4> Four cycles were completed by 86/100 of patients, 4/100 patients discontinued due to haematotoxicity, and 10/100 patients due to progressive disease. The treatment course was adjusted due to haematotoxicity in 24/100 patients, including postponed next cycle (n = 17), reduced administered activity (n = 13), and both adjustments (n = 10). The most observed haematotoxicity grade was grade 0–1 in 54/100 patients, grade 2 in 38/100 and grade 3–4 in 8/100. Significant differences in baseline leucocyte, neutrophil and platelet counts were observed between grade 0–1 and grade 2. However, the correlation between baseline and lowest observed values was poor to moderate. No differences between haematotoxicity grades and baseline parameters or somatostatin receptor positive tumour volume was observed. <h4>Conclusions</h4> The incidence of severe haematotoxicity was low with extensive screening and monitoring. The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment. Baseline parameters showed limited correlation with the degree of decline in haematological values.
format	article
author	Daphne M. V. de Vries–Huizing Michelle W. J. Versleijen Michiel Sinaasappel Iris Walraven Martine M. Geluk–Jonker Margot E. T. Tesselaar Jeroen J. M. A. Hendrikx Berlinda J. de Wit–van der Veen Marcel P. M. Stokkel
author_facet	Daphne M. V. de Vries–Huizing Michelle W. J. Versleijen Michiel Sinaasappel Iris Walraven Martine M. Geluk–Jonker Margot E. T. Tesselaar Jeroen J. M. A. Hendrikx Berlinda J. de Wit–van der Veen Marcel P. M. Stokkel
author_sort	Daphne M. V. de Vries–Huizing
title	Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
title_short	Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
title_full	Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
title_fullStr	Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
title_full_unstemmed	Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
title_sort	haematotoxicity during peptide receptor radionuclide therapy: baseline parameters differences and effect on patient’s therapy course
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/10f604e4a7ac41138d1d16ddeede3576
work_keys_str_mv	AT daphnemvdevrieshuizing haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT michellewjversleijen haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT michielsinaasappel haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT iriswalraven haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT martinemgelukjonker haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT margotettesselaar haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT jeroenjmahendrikx haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT berlindajdewitvanderveen haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse AT marcelpmstokkel haematotoxicityduringpeptidereceptorradionuclidetherapybaselineparametersdifferencesandeffectonpatientstherapycourse
_version_	1718413846435069952

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

Ejemplares similares